These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

773 related articles for article (PubMed ID: 18485407)

  • 1. Safety and side effects of immediate instillation of apaziquone following transurethral resection in patients with nonmuscle invasive bladder cancer.
    Hendricksen K; Gleason D; Young JM; Saltzstein D; Gershman A; Lerner S; Witjes JA
    J Urol; 2008 Jul; 180(1):116-20. PubMed ID: 18485407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer.
    Hendricksen K; Cornel EB; de Reijke TM; Arentsen HC; Chawla S; Witjes JA
    J Urol; 2012 Apr; 187(4):1195-9. PubMed ID: 22335860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer.
    Puri R; Palit V; Loadman PM; Flannigan M; Shah T; Choudry GA; Basu S; Double JA; Lenaz G; Chawla S; Beer M; Van Kalken C; de Boer R; Beijnen JH; Twelves CJ; Phillips RM
    J Urol; 2006 Oct; 176(4 Pt 1):1344-8. PubMed ID: 16952628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response.
    van der Heijden AG; Moonen PM; Cornel EB; Vergunst H; de Reijke TM; van Boven E; Barten EJ; Puri R; van Kalken CK; Witjes JA
    J Urol; 2006 Oct; 176(4 Pt 1):1349-53; discussion 1353. PubMed ID: 16952629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates.
    Jain A; Phillips RM; Scally AJ; Lenaz G; Beer M; Puri R
    Urology; 2009 May; 73(5):1083-6. PubMed ID: 19232688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
    Divrik RT; Yildirim U; Zorlu F; Ozen H
    J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Management of non invasive bladder cancers. T1Ga urothelial cell carcinoma: benefit of immediate post operative instillation?].
    Rouprêt M; Guillotreau J; Irani J; Zerbib M
    Prog Urol; 2010 Mar; 20 Suppl 1():S46-9. PubMed ID: 20493444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The orthotopic Fischer/AY-27 rat bladder urothelial cell carcinoma model to test the efficacy of different apaziquone formulations.
    Arentsen HC; Hendricksen K; Hulsbergen-van de Kaa CA; Reddy G; Oosterwijk E; Alfred Witjes J
    Urol Oncol; 2012; 30(1):64-8. PubMed ID: 19945311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer.
    Hendricksen K; van der Heijden AG; Cornel EB; Vergunst H; de Reijke TM; van Boven E; Smits GA; Puri R; Gruijs S; Witjes JA
    World J Urol; 2009 Jun; 27(3):337-42. PubMed ID: 19214526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apaziquone for Nonmuscle Invasive Bladder Cancer: Where Are We Now?
    Arends TJH; Alfred Witjes J
    Urol Clin North Am; 2020 Feb; 47(1):73-82. PubMed ID: 31757302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility of early intravesical instillation chemotherapy after transurethral resection of the bladder: a prospective evaluation in a consecutive series of 210 cases.
    Engeler DS; Wyler S; Neyer M; Hobi C; Müller J; Schmid HP
    Scand J Urol Nephrol; 2008; 42(6):522-7. PubMed ID: 18609290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
    Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC
    Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of intravesical instillation on performance of uCYT+ test.
    Lodde M; Mian C; Negri G; Vittadello F; Comploj E; Palermo S; Staffler A; Brössner C; Pycha A
    Urology; 2004 May; 63(5):878-81. PubMed ID: 15134970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histological changes due to intravesical instillation of mitomycin C.
    Castillo OA; Landerer E; Feria-Flores M; Vidal-Mora I; Franco C
    Arch Esp Urol; 2012 Jun; 65(5):578-82; discussion 582. PubMed ID: 22732786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder.
    Koga H; Kuroiwa K; Yamaguchi A; Osada Y; Tsuneyoshi M; Naito S
    J Urol; 2004 Jan; 171(1):153-7. PubMed ID: 14665865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical chemotherapy for superficial bladder tumors category Ta/T1: who should be treated and how?
    Kurth KH
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):30-5. PubMed ID: 8727808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of immediate instillation combined with regular instillations of pirarubicin for Ta and T1 transitional cell bladder cancer after transurethral resection: a prospective, randomized, multicenter study.
    Li NC; Ye ZQ; Na YQ;
    Chin Med J (Engl); 2013; 126(15):2805-9. PubMed ID: 23924446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study.
    Gudjónsson S; Adell L; Merdasa F; Olsson R; Larsson B; Davidsson T; Richthoff J; Hagberg G; Grabe M; Bendahl PO; Månsson W; Liedberg F
    Eur Urol; 2009 Apr; 55(4):773-80. PubMed ID: 19153001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis.
    Uchida A; Yonou H; Hayashi E; Iha K; Oda M; Miyazato M; Oshiro Y; Hokama S; Sugaya K; Ogawa Y
    Urology; 2007 Feb; 69(2):275-9. PubMed ID: 17320663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, pharmacokinetic and pharmacodynamic evaluation of apaziquone in the treatment of non-muscle invasive bladder cancer.
    Phillips RM; Hendriks HR; Sweeney JB; Reddy G; Peters GJ
    Expert Opin Drug Metab Toxicol; 2017 Jul; 13(7):783-791. PubMed ID: 28637373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.